The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid
- PMID: 11772589
- DOI: 10.1016/s0161-6420(01)00863-6
The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid
Abstract
Purpose: To determine the clinical outcome of patients with ocular-cicatricial pemphigoid (OCP) and the influence of systemic treatment on clinical progression.
Design: Noncomparative interventional case series.
Participants: Sixty-one patients with biopsy-proven OCP.
Methods: Patients with documented disease progression treated with chemotherapy and/or corticosteroids were followed between 1985 and 2000. The parameters evaluated were ocular stage at presentation, visual acuity, ocular complications, disease progression, control of ocular inflammation, and presence of extraocular involvement. Systemic treatment and related side effects were analyzed.
Main outcome measures: Visual acuity, ocular complications, extraocular involvement, disease progression, clinical outcome, systemic treatment, and related side effects.
Results: Sixty-one patients (32 female; 29 male) with a mean age of 67 years were studied. Extraocular involvement was present in 50% of patients. Sixty percent of eyes were initially seen with stage III (advanced cicatrizing) disease at first evaluation. Seven percent of involved eyes at first visit and 21% at the end of follow-up were legally blind. The most common ocular complications encountered were dry eye, corneal abnormalities, and glaucoma. Dapsone was the most commonly used drug (51 patients), followed by methotrexate (24 patients), azathioprine (23 patients), and cyclophosphamide (15 patients); prednisone, always given as adjunctive treatment, was used in 17 patients. Control of ocular inflammation (total or partial) was achieved in 90% of patients, but 46% of them needed continuation of systemic treatment to avoid disease recurrences, and 10% progressed despite different drugs used. Two agents were required in 32% of cases to control disease activity. The most common treatment-related side effects were hematologic complications (n = 34) followed by gastrointestinal (n = 17), cardiovascular (n = 15), and urinary complications (n = 11). Dapsone was responsible for the greatest number of side effects (n = 43); methotrexate caused the least trouble (n = 6). Corticosteroid-related complications (n = 34) were mostly cardiovascular and endocrinologic.
Conclusions: Ocular-cicatricial pemphigoid is an autoimmune disease that, untreated, progresses to conjunctival scarring and blindness; systemic immunosuppression is required to control it. Long-term systemic treatment and more than one drug are frequently necessary to avoid recurrences, exposing elderly patients to a higher risk of drug toxicity. The most frequently encountered treatment-related side effects were anemia, leukopenia, liver toxicity, and hypertension.
Similar articles
-
Methotrexate therapy for ocular cicatricial pemphigoid.Ophthalmology. 2004 Apr;111(4):796-801. doi: 10.1016/j.ophtha.2003.07.010. Ophthalmology. 2004. PMID: 15051215
-
[Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications].Ophthalmologe. 2000 Feb;97(2):113-20. doi: 10.1007/s003470050021. Ophthalmologe. 2000. PMID: 10734737 German.
-
Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.Ophthalmology. 2008 Feb;115(2):253-261.e1. doi: 10.1016/j.ophtha.2007.04.027. Epub 2007 Jul 26. Ophthalmology. 2008. PMID: 17655931
-
[Diagnostics and pharmacological treatment of ocular cicatrical pemphigoid].Klin Oczna. 2005;107(10-12):725-7. Klin Oczna. 2005. PMID: 16619831 Review. Polish.
-
Ocular cicatricial pemphigoid: manifestations and management.Curr Allergy Asthma Rep. 2005 Jul;5(4):333-8. doi: 10.1007/s11882-005-0078-9. Curr Allergy Asthma Rep. 2005. PMID: 15967079 Review.
Cited by
-
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.J Eur Acad Dermatol Venereol. 2021 Oct;35(10):1926-1948. doi: 10.1111/jdv.17395. Epub 2021 Jul 26. J Eur Acad Dermatol Venereol. 2021. PMID: 34309078 Free PMC article.
-
Incidence and Outcomes of Cataract in Eyes with Ocular Cicatricial Pemphigoid.Ocul Immunol Inflamm. 2025 Jul;33(5):791-799. doi: 10.1080/09273948.2025.2450471. Epub 2025 Feb 5. Ocul Immunol Inflamm. 2025. PMID: 39908486
-
Ab Interno Goniotomy with the Kahook Dual Blade in a Monocular Patient with Mucous Membrane Pemphigoid and Refractory Open Angle Glaucoma: A Case Report.Int Med Case Rep J. 2022 Oct 11;15:563-568. doi: 10.2147/IMCRJ.S382810. eCollection 2022. Int Med Case Rep J. 2022. PMID: 36313053 Free PMC article.
-
NGF Modulates trkANGFR/p75NTR in αSMA-Expressing Conjunctival Fibroblasts from Human Ocular Cicatricial Pemphigoid (OCP).PLoS One. 2015 Nov 16;10(11):e0142737. doi: 10.1371/journal.pone.0142737. eCollection 2015. PLoS One. 2015. PMID: 26569118 Free PMC article.
-
Immunomodulatory Effects of Taiwanese Neolitsea Species on Th1 and Th2 Functionality.J Immunol Res. 2017;2017:3529859. doi: 10.1155/2017/3529859. Epub 2017 Jul 11. J Immunol Res. 2017. PMID: 28781969 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical